Skip to main content

and
Your search also matched 3 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma

Include preview-only content
  1. Article

    Open Access

    Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis

    Chongbiao Huang, Hui Li, Yang Xu, Chao Xu in Signal Transduction and Targeted Therapy (2024)

  2. Article

    Open Access

    Correction: RIPK1-dependent necroptosis promotes vasculogenic mimicry formation via eIF4E in triple-negative breast cancer

    Fan Li, Huizhi Sun, Yihui Yu, Na Che, Jiyuan Han, Runfen Cheng in Cell Death & Disease (2023)

  3. Article

    Open Access

    BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis

    VEGF inhibitors are one of the most successful antiangiogenic drugs in the treatment of many solid tumors. Nevertheless, pancreatic adenocarcinoma (PAAD) cells can reinstate tumor angiogenesis via activation o...

    Chongbiao Huang, Hui Li, Yang Xu, Chao Xu in Signal Transduction and Targeted Therapy (2023)

  4. Article

    Open Access

    RIPK1-dependent necroptosis promotes vasculogenic mimicry formation via eIF4E in triple-negative breast cancer

    Necroptosis is a caspase-independent form of programmed cell death. Receptor interacting protein kinase 1 (RIPK1) is a key molecule in the initiation of necroptosis and the formation of the necrotic complex. V...

    Fan Li, Huizhi Sun, Yihui Yu, Na Che, Jiyuan Han, Runfen Cheng in Cell Death & Disease (2023)

  5. Article

    Open Access

    Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis

    Chemoresistance is the main reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and compounds to reverse chemotherapeutic resistance.

    Tianxing Zhou, Yongjie **e, Xupeng Hou in Journal of Experimental & Clinical Cancer … (2023)

  6. Article

    Open Access

    ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour–stromal IL-1β/NF–κB/ESE3 signalling axis

    Desmoplastic stroma, a feature of pancreatic ductal adenocarcinoma (PDAC), contains abundant activated pancreatic stellate cells (PSCs). How PSCs promote PDAC progression remains incompletely understood.

    Tiansuo Zhao, Di **ao, Fanjie **, Xugang Sun, Jie Yu in British Journal of Cancer (2022)

  7. Article

    Open Access

    Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression

    Interleukin 35 (IL-35) is a novel member of the IL-12 family, consisting of an EBV-induced gene 3 (EBI3) subunit and a P35 subunit. IL-35 is an immune-suppressive cytokine mainly produced by regulatory T cells...

    Chongbiao Huang, Na Li, Zengxun Li, Antao Chang, Yanan Chen in Nature Communications (2017)